-

Agilent Introduces Three New Microarrays for Prenatal and Postnatal Research

Delivering up-to-date content for cytogenetic testing needs

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today introduced three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal research.

The new Agilent GenetiSure Cyto microarrays include updated, clinically relevant content from respected databases. The probes on the Cyto microarrays provide high-resolution detection of copy number variations, and copy-neutral loss of heterozygosity associated with developmental delay, neuropsychiatric disorders, intellectual disability, congenital anomalies, or unexplained dysmorphic features in constitutional DNA samples.

“With the progression of next-generation sequencing, new gene-disease associations are being uncovered, and databases are evolving rapidly to include these discoveries,” said Kevin Meldrum, general manager of Agilent’s Genomics Solution Division. “Clinical researchers need to have a platform that will allow them to test for these relevant genetic aberrations.”

Meldrum noted that Agilent’s new arrays focus on clinically relevant regions with different specifications, depending on application (prenatal and postnatal research) down to exon-level resolution.

Dr. Svetlana Yatsenko, who directs the cytogenetics laboratory at the University of Pittsburgh Medical Center’s Magee-Women’s Hospital, in Pittsburgh, Pennsylvania, had this to say about the new microarrays:

“As a high-volume molecular cytogenetics laboratory, one of our key needs is having a microarray platform that contains the latest clinically-relevant content. Agilent GenetiSure Cyto microarrays meet this need. With a targeted design covering over 3600 genes and compatibility with a wide range of clinically relevant samples, we see it as a compelling solution for any laboratory trying to implement or upgrade their microarray testing needs.”

Agilent is a leading manufacturer of high-quality microarrays for copy number analysis and provides a complete workflow from sample preparation to interpretation.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Reports Fourth-Quarter Fiscal Year 2025 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.86 billion for the fourth quarter ended October 31, 2025, exceeding revenue guidance and representing growth of 9.4% reported and up 7.2% core(1) compared with the fourth quarter of 2024. Fourth-quarter GAAP net income was $434 million, or $1.53 per share. This compares with $351 million, or $1.22 per share, in the fourth quarter of 2024. Non-GAAP(2) net income was $452 million, or $1.59 per...

Agilent Announces Cash Dividend of 25.5 Cents Per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on Jan. 28, 2026, to all shareholders of record as of the close of business on Jan. 6, 2026. The timing and amounts of future dividends are subject to the determination and approval by Agilent’s board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical...

Agilent to Participate in Citi’s 2025 Global Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chief Enterprise Transformation Officer Tom Callihan and Head of Investor Relations Tejas Savant will participate in a fireside chat at Citi’s 2025 Global Healthcare Conference. The event is scheduled for 9 to 9:45 a.m. EDT on Thursday, Dec. 4, 2025, in Miami, Florida. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Tech...
Back to Newsroom